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Background: In general, opioid use as labor analgesic has been associated with some maternal and neonatal side effects 
including maternal sleepiness and reduced neonatal Apgar score among other side effects. In view of this, many mothers 
have been undergoing labor without analgesia. The search for safer and effective alternative has continued over the years.
Objective: The study was aimed at comparing the efficacy and side effect profile of intramuscular paracetamol and 
intramuscular pethidine as analgesia in labor.
Study Design: This study is a prospective randomized double‑blind comparative study.
Materials and Methods: Two groups of 54 consenting parturients each were recruited following a computer‑generated 
randomization pattern. Parturients in one group had 600 mg of intramuscular paracetamol and the other 50 mg intramuscular 
pethidine, and mean pain reduction at 30 min, 1, 2, 3, and 4 h was obtained using a visual analog scale in both groups and 
compared. Demographic data and primary and secondary outcomes of both groups were compared using t‑test (for quantitative 
measures). The Statistical Package for the Social Sciences (SPSS) version 17 was used for statistical analysis.
Results: There was comparable efficacy of labor pain reduction in paracetamol and pethidine after 1 h of drug administration 
and up till 3 h after (P < 0.001), however, pain reduction was more in pethidine group as expected. The maternal and fetal 
side effect profile of paracetamol was found to be better than that of pethidine.
Conclusion: This study has shown that paracetamol can be used for labor pain with the added advantage of better side 
effect profile as compared with pethidine.
Key words: Analgesic; intramuscular; labor; paracetamol; pethidine.
Introduction
Childbirth is a painful process right from the first delivery 
on the earth, and it has been with pains in accordance with 
Gods commands in Genesis 3:16 of the Holy Bible.[1]
Several groups of people think that God has made this process 
painful, and no interference should be done in it.[2] However, 
as the world has evolved, technological innovations and 
advancement have changed or affected almost all aspects of 
life in one way or the other. In the present civilization, there is 
no circumstance where it is considered acceptable for a person 
to experience severe pain, amenable to safe intervention while 
under a physician’s care.[3] While most people are aware of 
the association of labor with pain, the majority of parturients 
are not aware of the appropriateness of labor pain relief and 
the modalities of doing so. The level of acceptance of labor 
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analgesia after full information was found to be significantly 
correlated with the level of education and socioeconomic 
status, fear of delivery complications, fear of labor pains, and 
their eagerness to deliver without suffering from labor pains.[4]
In Nigeria, it is generally assumed that labor is well tolerated, 
and pain relief is not usually considered an important part of 
intrapartum care. In a study at Wesley Guild Hospital, Ilesa, 
the majority 68.3% of women described labor pain as severe. 
Only 5.3% described it as mild.[5]
In a questionnaire survey done at the Antenatal Clinic of the 
Federal Medical Centre, Owo, purposely for this study, of the 
60 pregnant women interviewed, 43 (71.67%) indicated that 
they were unaware of availability of drugs that can be used 
to relieve labor pains while 17 (28.33%) said that they were 
aware. However, 52 (86.67%) said that they were willing to 
utilize any available means of relieving labor pains when they 
come in labor. Of the 32 of them that have delivered before, 
only 4 (12.50%) had analgesia in their previous deliveries.
In the modern era, various nonpharmacological and 
pharmacological methods are being practiced for labor 
analgesia. The various nonpharmacological techniques of 
labor analgesia include psychoprophylaxis such as breathing 
exercise, music therapy, doula, hypnosis, hydrotherapy, 
acupuncture, and acupressure. Others are yoga and 
transcutaneous electrical nerve stimulation.[6]
The various pharmacological methods available include 
parenteral opioids such as pethidine, pentazocine, fentanyl, 
remifentanil, and sufentanil and nonopioids such as tramadol.
Pethidine is a controlled drug that is prone to be abused 
by health caregivers or patients making it not to be readily 
available despite being inexpensive. It has also been found 
to be associated with maternal sleepiness and reduced 
neonatal Apgar score among other side effects. Considering 
the various challenges limiting the use of above-mentioned 
analgesia, many mothers have been undergoing labor without 
analgesia because of the fear of the fetomaternal side effects 
and other associated challenges. The search for safer and 
effective alternatives has continued over the years.
Then, in 1950, pethidine was made available to midwives, 
in the belief that it had the analgesic effect of morphine but 
without its side effects. It was also widely believed to be a 
more powerful analgesic than nitrous oxide. These assertions 
were found to be wrong as quite quickly, the ineffectiveness 
of pethidine,[7] and its adverse effects on the newborn[8] began 
to emerge, but these findings were often ignored. In the fetus, 
breathing movements, muscular activity, oxygen saturation, 
and short-term heart rate variability are all reduced following 
maternal pethidine.[9]
The impact of these changes on the outcome is unclear, 
but there is no doubt that numerous adverse effects are 
observed also in the newborn. Neonatal sequelae of pethidine 
are prolonged. Neonatal respiratory depression has been 
extensively documented and is worst if pethidine is given 
repeatedly and 3 h or more before delivery and least if given 
only within the last hour of labor.[10,11] Large doses of pethidine 
depress the Apgar scores,[9] but though smaller doses may not, 
it must be remembered that Apgar scores are only applicable 
to the first few minutes of life, a stimulating time for the 
newborn, who may later become severely depressed. Indeed 
reduced oxygen saturation, increased carbon dioxide levels 
and metabolic acidosis have been observed in the first few 
hours of life, even after small doses of pethidine.[12,13]
Various substitutes for pethidine have been introduced, with 
the intent of producing superior labor analgesia without 
neonatal depression hitherto seeming to be a forlorn 
hope. Unfortunately, fetal and neonatal outcomes for these 
alternative drugs have been even less thoroughly studied 
than those of pethidine, surely an omission, given its many 
known adverse neonatal effects.[14]
In a study that reviewed the perception and practice of 
epidural analgesia among women attending the antenatal 
clinic in Federal Teaching Hospital, Abakaliki, about 43.3% 
of respondents are aware of the use of epidural analgesia 
in labor, but only 7.5% had used it. About 95% of these 
were satisfied and desire to use it again. The desire to 
experience natural labor, cost, and fear of side effects were 
part of reasons for not using.[15] Other challenges of obstetric 
analgesia in Nigeria include lack of resources, competing 
priorities, and death of anesthesiologists.[16]
Nonopioid medications for analgesia are drugs that 
have principally analgesic, antipyretic, anti-inflammatory 
actions with or without sedative effect. These include 
acetaminophen (paracetamol) ,  the nonsteroidal 
anti-inflammatory drugs (NSAIDs) such as aspirin and 
antispasmodic drugs such as hyoscine.[17]
Paracetamol is the active metabolite of phenacetin, 
once popular as an analgesic and antipyretic in its own 
right. However, unlike phenacetin and its combinations, 
paracetamol is not carcinogenic at therapeutic doses.[18] 
The words acetaminophen (used in the United States,[19] 
Canada, Japan, South Korea, Hong Kong, and Iran) and 
paracetamol (used elsewhere) both come from a chemical 
name for the compound: para-acetylaminophenol and 
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para-acetylaminophenol by taking the underlined alphabets 
together to form acetaminophen and paracetamol, 
respectively. In some contexts, it is simply abbreviated as 
APAP for acetyl-para-aminophenol.
Paracetamol is used for the relief of pains associated with 
many parts of the body. It has analgesic properties comparable 
to those of aspirin, whereas its anti-inflammatory effects are 
weak. Its better tolerated than aspirin in patients in whom 
excessive gastric acid secretion or prolongation of bleeding 
time may be a concern. Available without prescription, it is 
on the World Health Organization (WHO) list of essential 
medicines,  the most effective and safe medicines needed in a 
health system.[20] Regarding comparative efficacy, studies show 
conflicting results when compared to NSAIDs. A randomized 
controlled trial of chronic pain from osteoarthritis in adults 
found similar benefits from paracetamol and ibuprofen.[21] In 
recommended doses and for a limited course of treatment, 
the side effects of paracetamol are mild to nonexistent.[22] 
Paracetamol is part of the class of drugs known as “aniline 
analgesics,” and it is the only such drug still in use today.[23] It 
was discovered in the 1890s and marketed as painkiller since 
1950s. To date, the mechanism of action of paracetamol is 
not completely understood. The main mechanism proposed 
is the inhibition of cyclooxygenase (COX), and recent findings 
suggest that it is highly selective for COX-2.[24]
The COX family of enzymes is responsible for the metabolism 
of arachidonic acid to prostaglandin H2, an unstable molecule 
that is in turn, converted to numerous other pro-inflammatory 
compounds. Classically, anti-inflammatories such as the 
NSAIDs block this step. Only when appropriately oxidized 
is the COX enzyme highly active,[25,26] paracetamol reduces 
the oxidized form of the COX enzyme, preventing it from 
forming pro-inflammatory chemicals.[27,28] This leads to a 
reduced amount of prostaglandin E2 in the central nervous 
system, thus lowering the hypothalamic set point in the 
thermoregulatory center.
An Egyptian University double-blind, randomized trial that 
evaluated the efficacy of intravenous infusion of paracetamol 
as intrapartum analgesia in the first stage of labor, the efficacy 
of intravenous infusion of paracetamol in comparison with 
placebo[28] in laboring women starting from the time of 
medication till the end of the first stage of labor. Participants 
were followed for the duration of labor, an expected average of 8 
h, and the degree of pain and the need for an additional analgesia 
were noted and assessed with the visual analog scale (VAS).
This local pilot single-arm trial in Ain Shams University Hospital, 
Cairo, Egypt, provided reassuring data regarding this new use 
of the drug, but it did not have a comparison arm.[29]
Another study in Egypt evaluated the efficacy and adverse effects 
of an intravenous infusion of 1000 mg of paracetamol during the 
active phase of labor as compared with an intravenous injection 
of 50 mg of pethidine hydrochloride as a method for intrapartum 
analgesia.[30] One hundred and two participants were enrolled in the 
study. All of the participants in the two groups were primigravidae in 
the active phase of labor with comparable age, gestational age, body 
mass index (BMI) (at the end of pregnancy), and cervical dilatation. 
Compared with the pretreatment score, the mean VAS score was 
lower at 15 min, 1, and 2 h after treatment in both groups. There was, 
however, no reduction in score after 3 h in either group; conversely, 
there was an increase in VAS score after 4 h in comparison to the 
initial score. Adverse maternal and fetal effects were recorded only 
in the pethidine group, in which 32 women (64%) had one or more 
of the following symptoms: dizziness, blurred vision, dryness of the 
mouth, vomiting, dyspnea, tachycardia, and a significant change in 
blood pressure; in addition, fetal bradycardia was recorded in two 
women in the pethidine group.
The conclusion from the study was that the effectiveness 
of intravenous paracetamol was comparable to that of 
intravenous pethidine, but paracetamol had fewer maternal 
adverse effects. However, pain reduction in the first 15 min 
of administration was more in the pethidine group because 
of its more rapid onset of action. The study also suggests that 
paracetamol causes shortening of the active phase of labor 
as compared with pethidine. From available information, the 
only drug that has been shown to shorten the duration of 
labor is hyoscine N-butyl bromide (hyoscine).[31,32] It is thought 
that hyoscine acts as a cervical spasmolytic.[33]
This presumed effect of paracetamol is intriguing and 
warrants further and future study. If shown to be true, 
paracetamol would be advantageous as a single medicament 
for intrapartum analgesia as compared with pethidine with 
shortening of labor duration as added benefit.
Aim of the study
This study explored the possibility of the use of intramuscular 
paracetamol, a readily available and cheap analgesic without the 
various side effects associated with pethidine for labor analgesia.
Objectives of the study
General objective
The study was aimed at comparing the use of intramuscular 
paracetamol and intramuscular pethidine as analgesics in 
labor.
Specific objectives
1. To compare the efficacy of intramuscular paracetamol 
and intramuscular pethidine as analgesics in the first 
stage of labor
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2. To compare the fetomaternal side effect profile of 
paracetamol and that of pethidine when used as 
analgesic in the first stage of labor.
The hypotheses
Null hypothesis
1. The efficacy of intramuscular paracetamol is not 
similar to that of intramuscular pethidine when used as 
analgesics in the first stage of labor
2. Fetomaternal side effect profile of paracetamol is not 
better than that of pethidine when used as analgesic in 
the first stage of labor.
Alternate hypothesis
1. The efficacy of intramuscular paracetamol is similar to 
that of intramuscular pethidine when used as analgesics 
in the first stage of labor
2. Fetomaternal side effect profile of paracetamol is better 
than that of pethidine when used as analgesics in the 
first stage of labor.
Materials and Methods
Study site
The study was carried out at the Department of Obstetrics 
and Gynaecology of the Federal Medical Centre, Owo, 
Ondo State, Nigeria. The hospital has an average of 1600 
total deliveries every year and serves as referral center for 
hospitals in Ondo State, parts of Ekiti, Edo, Kogi, and Osun 
States.
Study design
This study is a randomized comparative clinical study 
in which a double-blinded interventional approach was 
adopted. This single-centered, randomized clinical trial 
recruited women in labor presenting for delivery at the 
labor ward of the Federal Medical Centre, Owo. Following 
approval of the study protocol by the hospital research 
and ethics committee, all women fulfilling the recruitment 
criteria received informative discussion about the nature 
of the study. Those that agreed to enter the study signed 
written informed consent.
Study population
The study population consisted of parturients that are 
primigravida who are in active phase of labor from 4 cm to 
7 cm cervical dilatation and that are having pains requiring 
analgesia. The pregnancies were at term, with normal 
singleton fetus in cephalic presentation, longitudinal lie. 
They qualified for classification into the American Society 
of Anesthesiologists physical status I and II (ASA I-II).
Exclusion and inclusion criteria
Exclusion criteria
The exclusion criteria include previous cesarean section, 
hypertension, preeclampsia, eclampsia, intrauterine growth 
retardation, intrauterine fetal death, morbid obesity, and 
allergy to any of the study drugs. Others are extremes of 
ages (<18 years and > 35 years), multiparity, multiple gestations, 
malpresentation, cephalopelvic disproportion, induction of labor, 
scarred uterus, fetal distress, antepartum hemorrhage, and use 
of any other kind of analgesia before recruitment to the study.
Inclusion criteria
The inclusion criteria are primigravida low-risk parturients aged 
18–35 years, spontaneous onset of labor at term (37–42 weeks 
gestation), cervical dilatation of 4–7 cm with adequate uterine 
contractions, and a single live fetus in cephalic presentation. 
Cervical dilatation and demographic data, including age, 
gestational age, and BMI (BMI; calculated as weight in kilograms 
divided by the square of height in meters), were recorded.
Patient information and consent taking
All eligible women were informed about the study using 
the patient information sheet and were appropriately 
counseled. Patients who cannot read or write English had 
their questionnaires interpreted to them. Informed written 
consent was obtained. All eligible women who gave written 
consent were recruited for this study.
Ethical considerations
Ethical clearance was obtained from the institutional ethical 
committee. Verbal and written consent were obtained from 
the participants as well. Patients refusal to participate in 
the study were respected with no attempt at coercion 
or inducement to gain consent. Moreover, the decline in 
participation by any patient did not adversely affect their 
management in any way.
Confidentiality of information was ensured by the use of 
initials to identify patients.
Sample size determination
The minimum sample size for the study was calculated using 
the following formula:[34] N = 2 (zα + zβ)
2/(δ/σ)2. This gave 
the minimum total sample size to 108.
Methodology
One hundred and twenty patients were recruited to include 
10% attrition. One hundred and eight were analyzed. After 
enrollment, each participant was allocated the next available 
number in a concealed sequence of a computer-generated 
randomization plan, which determined the drug that was 
used. The participants were randomly allocated to 1 of 2 
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groups, paracetamol = 1 and pethidine = 2 groups. In the 
paracetamol group (n = 54), women received a 600 mg (4 ml) 
of intramuscular paracetamol with the same brand used for 
all participants in the group; in the pethidine group (n = 54), 
women received an intramuscular injection of 50 mg (1 ml) 
pethidine hydrochloride, same brand for all participants in 
this group.
Pain was assessed with the VAS. Participants reported pain 
intensity on a 100-mm VAS, bounded by “no pain” and “the 
worst pain,” immediately before receiving the study drug 
and at 30 min, 1, 2, 3, and 4 h after drug administration. The 
primary outcome measure was the efficacy of the drug to 
supply adequate analgesia as was measured by a change in the 
VAS pain intensity score after drug administration. A mean 
reduction in VAS score of 30 mm represents a clinically 
important difference in pain severity that corresponds to 
patients perception of adequate pain control.[35]
Management of labor was done according to the hospital’s 
protocols with artificial rupture of membranes done as 
required.
Justification
There is a need to continue to explore more options of 
obstetric analgesia. Intramuscular route of administration was 
favored in consideration of the intended applicability of the 
study because of challenges in instituting intravenous therapy, 
especially in low-resource or developing parts of the world. 
The skills and personnel to establish and monitor intravenous 
access may not be available in primary health centers and 
maternity homes where most of the deliveries take place. It is 
also safer to avoid oral intake during established labor because 
of problems of possible aspiration in case vomiting occurs, or 
there is a need for emergency operative intervention.
Data collection: Instrument
Pain assessment was performed by only one person, the 
researcher, who had no role in patient enrollment and was 
blind to the drug administration. A VAS was used to assess 
pain before drug, 30 min, 1, 2, 3, and 4 h after drug. Pain 
was not assessed after 4 h because, despite the possibility 
of repeated drug intake, it was estimated that by then, more 
than 50% of participants would have delivered either vaginally 
or by cesarean section.
The baseline maternal and fetal vital sign parameters were 
recorded, and this was repeated at each time pain assessment 
was done.
Spontaneously observed and reported adverse events both 
maternal (dizziness, tachycardia, dyspnea, vomiting, blurred 
vision, dryness of the mouth, and significant changes in blood 
pressure	[≥30	mmHg	systolic	or	≥15	mmHg	diastolic])	and	
fetal or neonatal (nonreassuring cardiotocography including 
fetal tachycardia, low Apgar scores at 1 and 5 min, and need 
for admission to the intensive care unit [ICU]) were looked 
out for and noted. The interval between drug administration 
and delivery was also recorded.
The primary outcome measure was the efficacy of the drug 
to supply adequate analgesia, as measured by a change in 
the VAS pain intensity score at 30 min, 1, 2, 3, and 4 h after 
drug administration. When responding to the visual analog 
item, respondents specified their level of agreement to a 
statement by indicating a position along a continuous line 
between two endpoints of a straight line on a plane white 
paper. Participants reported pain intensity on a 100-mm VAS, 
bounded by “no pain” and “the worst pain,” immediately 
before receiving the study drug and at 30 min, 1, 2, 3, and 
4 h after drug administration.
Secondary outcome measures included the need for 
additional analgesia and the presence of maternal or fetal 
adverse events during the study.
Data presentation
Data were presented as descriptive statistics (range, mean, 
and standard deviation [SD] for metric data; and range, 
median, and interquartile range for discrete data).
Data analysis
The Statistical Package for the Social Sciences (SPSS) 
version 17.0 (SPSS Inc., Chicago) was used for data statistical 
analysis. Demographic data and primary and secondary 
outcomes of both groups were compared with t-test (for 
quantitative measures). Categorical variables were compared by 
cross tabulation with Chi-square and significance determined. 
Charts were produced using the chart builder soft wear on SPSS.
Limitation(s) of the study
The initial limitation experienced was that of getting 
pethidine because it is a controlled drug that could not be 
purchased by an individual or over the counter. However, 
this was surmounted by liaison with the Hospital’s Director 
of Pharmaceutical Services that facilitated the use of the 
hospitals platform to stuck the Hospital’s pharmacy with the 
drug from the Nigeria Central Drug Store.
Results
The sample size for this study was 108 which excludes the 
10% number of nonresponse (attrition). The total number of 
patients interviewed was 120 of which 108 were recruited for 
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the study. Of the 108 pregnant women recruited, 67 (62.0%) 
were booked while 41 (38.0%) were unbooked patients of the 
Federal Medical Centre, Owo, Ondo State [Table 1]. Most of 
the women were self-employed, 53 (49.1%). Yoruba ethnic 
group accounted for 86.1% of recruited patients [Table 1]. 
Majority of the recruited patients were in the age range of 
25–34 years [Table 1]. Other sociodemographic data analyzed 
revealed that 99 (91.7%) of 108 patients were married, while 
9 (8.3%) were not married but had partners. The Olusanya 
et al. system of social class classification was used to allocate 
recruited patients into social classes. This revealed that 
38 (35.18%) were in social Class 1, 41 (37.96%) were in social 
Class 2, while 29 (26.85%) were in Class 3. All the patients 
recruited were at term with the lowest and highest gestational 
ages of 37 and 42 weeks, respectively. It was observed that 
89 (82.45%) parturients had their labor in lateral position 
making it to be the most adopted labor position in this study. 
Eighteen (16.67%) adopted dorsal position while 1 (0.93%) 
preferred to sit. Adopted labor positions were almost equally 
distributed among the two groups. The BMI of all patients 
recruited ranged from 20.90 kg/m2 to 29.10 m2 [Table 2]. The 
mean BMI was 24.63 kgm2 and 25.00 kgm2 for paracetamol 
and pethidine groups, respectively.
All the patients recruited were at cervical dilatation of 4 cm or 
5 cm at the time of administration of the drug. The mean cervical 
dilatation before drug administration was 4.43 ± 0.57 cm and 
4.6 ± 0.72 cm for paracetamol and pethidine, respectively.
This study revealed that labor pains are highly rated by 
parturients with 107 (99.1%) paturients having VAS score of at 
least 9 over a maximum score of 10 before administration of 
analgesic. Only 1 (0.9%) parturient had a VAS score of 8 which 
is still a considerably high pain score. The mean baseline VAS 
score for the two groups was 9.7 and 9.8, respectively. Both 
paracetamol and pethidine reduced labor pains significantly 
as revealed in this study though pain reduction was less in the 
paracetamol group than the pethidine group. However, VAS 
score started to increase after 2 h in both groups [Table 3].
The mean pain reductions 30 min after administration of 
analgesic were 1.96 ± 0.82 cm and 3.00 ± 1.12 cm for 
paracetamol and pethidine, respectively, t	=	−5.495	 and 
P < 0.005 [Table 4]. At 1 h after drug administration, mean 
pain reductions were 3.07 ± 0.08 and 4.09 ± 1.12 cm, for 
paracetamol and pethidine, respectively, t	=	−5.949	 and 
P < 0.005. At 2 h after drug, mean pain reductions were 
3.39 ± 0.92 and 4.61 ± 1.04 cm for paracetamol and pethidine, 
respectively, t	=	−6.489	and P < 0.005. At 3 h after drug 
administration, the mean pain reductions were 3.11 ± 1.00 cm 
and 4.30 ± 1.14 cm, t	=	−5.726	 and P < 0.005. At 4 h 
after drug administration, the mean pain reductions were 
2.50 ± 0.947 cm and 3.61 ± 1.172 cm for paracetamol and 
pethidine, respectively, t	=	−1.106	 and P < 0.005. Pain 
reduction was more in pethidine group as expected.
The interval between drug administration and delivery 
was 5.24 ± 1.12 h and 5.50 ± 1.31 h for paracetamol and 
pethidine, respectively, t	=	−1.106	and P = 0.271.
The mean Apgar score of the babies at 1 min after the 
administration of analgesics was 8.67 ± 0.614 and 
7.85 ± 0.656 in the paracetamol and pethidine groups, 
respectively, t = 6.662 and P < 0.005. At 5 min, the 








15‑19 1 (1.9) 1 (1.9) 2 (1.9)
20‑24 17 (31.5) 13 (24.1) 30 (27.8)
25‑29 22 (40.7) 29 (53.7) 51 (47.2)
30‑34 13 (24.1) 9 (16.7) 22 (20.4)
35‑39 1 (1.9) 2 (3.7) 3 (2.8)
Booking status
Booked 30 (55.6) 37 (68.5) 67 (62.1)
Unbooked 24 (44.4) 17 (31.5) 41 (37.9)
Employment status
Self employed 29 (53.7) 24 (44.4) 53 (49.1)
Salary earner 13 (24.1) 20 (37.0) 33 (30.6)
Not employed 1 (1.9) 4 (7.4) 5 (4.6)
Farming 3 (5.6) 4 (7.4) 7 (6.5)
Student 8 (14.8) 2 (3.7) 10 (9.3)
Ethnicity
Yoruba 47 (87.0) 46 (85.2) 93 (82.3)
Hausa 1 (1.9) 2 (3.7) 3 (2.7)
Edo 1 (1.9) 2 (3.7) 3 (2.7)
Ebira 5 (9.3) 3 (5.6) 8 (7.1)
Igbo 0 1 (1.9) 1 (0.9)
Marital status
Married 47 (87.0) 52 (96.3) 99 (91.7)
Single 7 (13.0) 2 (3.7) 9  (8.3)
Values are given as number and percentages from cross tabulation of the two groups. 
Age group: Pearson’s χ2=2.555, P=0.635; Booking Status: Pearson’s χ2=1.926, 
P=0.165; Employment: Pearson’s χ2=7.499, P=0.112; Ethnicity: Pearson’s χ2=2.177, 
P=0.703; Marital status: Pearson’s χ2=3.030, P=0.080







Age (years) 26.52±4.01 26.81±3.50 −0.405 0.686
Gestational age (weeks) 38.69±1.21 39.04±1.34 −1.421 0.158
BMI (kg/m2) 24.62±1.81 25.00±1.57 −1.14 0.257
Cervical dilation before drug (cm) 4.43±0.57 4.46±0.719 −0.297 0.767
Baseline VAS (cm) 9.72±0.49 9.78±0.420 −0.631 0.529
Values  are  given  as mean with  95% CI.  VAS, Visual  analog  scale; BMI, Body mass 
index; CI, Confidence interval
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mean Apgar scores of the neonates were 9.93 ± 0.264 
and 9.97 ± 0.536 for paracetamol and pethidine groups, 
respectively, t = 4.329 and P < 0.005 [Table 5].
All side effects noticed in this study occurred in the pethidine 
group as ten (10) parturients experienced dizziness after 
administration of analgesic in pethidine group while no 
parturient in the paracetamol group experienced dizziness 
after drug administration (t = 2.011, P < 0.047). Seven 
parturients had vomiting (t = 2.810 and P < 006) while 
three other parturients also had dry mouth after drug 
administration all in the pethidine group (t = 2.059, and 
P = 0.042) [Table 6].
No parturient had tachycardia, blurring of vision, or dyspnea 
after drug administration in this study. The most common 
side effect of pethidine in this study was dizziness which 
was experienced by ten parturients accounting for 18.52% 
of parturients in the pethidine group. Four parturients in the 
paracetamol group and five in the pethidine group eventually 
had cesarean section due to other obstetric indications and 
not fetal distress or prolonged labor.
Three (5.5% of parturients in pethidine group) neonates 
had temporary inability to suck well within the first few 
hours after delivery while none had similar experience in 
the paracetamol group (t = 1.766 and P = 0.080) [Table 6].
The maternal vital signs were essentially not affected 
by either of the drugs given [Table 5], and there was no 
significant effect of any of the two analgesics on the fetal 
heart rate of the neonates delivered [Table 7].
There were no any other neonatal abnormalities detected in 
any of the groups [Table 6].
Discussion
This study which compared the use of intramuscular 
paracetamol and pethidine as labor analgesic in the first 
stage of labor has shown that the use of intramuscular 
paracetamol injection for intrapartum analgesia in the first 
stage of labor is effective. A mean reduction in VAS score 
of 3 cm represents a clinically important difference in pain 
severity that corresponds to patients perception of adequate 
pain control[35] and makes patients feel relative comfort since 
pain may not be totally eliminated in labor. This was achieved 
with the use of paracetamol 1 h after administration and 
sustained up to 3 h after paracetamol was administered. 
Therefore, analgesic effect of paracetamol lasted for at 
least 2 h, as determined by the significant reduction in pain 
at 1, 2, and 3 h in comparison to the pretreatment pain 
score. It was, however, noticed that the significant pain 
reduction was achieved earlier in the pethidine group at 
30 min after administration due to its rapid onset of action, 
moreover, pethidine produced more sustained relief of pain 
as depicted by the VAS scores. This is similar to the results 
Table 3: Visual analog scale score in the two groups after drug 
administration
Paracetamol (n=54) Pethidine (n=54) t P
At 30 min 7.76±0.775 6.78±1.040 5.559 <0.001
At 1 h 6.65±0.756 5.59±1.019 6.112 <0.001
At 2 h 6.33±0.869 5.17±0.927 6.750 <0.001
At 3 h 6.61±0.979 5.48±1.059 5.754 <0.001
At 4 h 7.28±0.979 6.17±1.077 5.608 <0.001
Values are given as mean VAS score at different times of assessment after drug 
administration  (95% CI).  VAS, Visual  analog  scale; CI,  Confidence  interval
Table 4: Reduction in pain scale score (visual analog scale) 
after drug administration
Paracetamol (n=54) Pethidine (n=54) t P
30 min 1.96±0.82 3.00±1.17 −5.49 <0.001
1 h 3.07±0.79 4.19±1.12 −5.95 <0.001
2 h 3.39±0.92 4.61±1.04 −6.49 <0.001
3 h 3.11±1.00 4.30±1.14 −5.73 <0.001
4 h 2.50±0.95 3.61±1.17 −5.35 <0.001
Values are given as mean  reduction±SD of VAS score after  drug administration  (95% CI). 
SD, Standard deviation; VAS, Visual analog scale; CI, Confidence interval









Paracetamol 76±5 120.4±9.5 76.1±8.9
Pethidine 76±4 121.7±7.9 79.4±7.3
P 0.580 0.827 0.038
30 min
Paracetamol 77±4 119.8±9.2 78.1±8.0
Pethidine 77±4 119.6±6.9 80.0±6.8
P 0.860 0.907 0.204
1 h
Paracetamol 77±4 119.3±8.7 79.1±8.3
Pethidine 77±4 118.7±6.2 80.6±6.8
P 0.740 0.608 0.302
2 h
Paracetamol 76±4 119.3±8.6 79.3±8.4
Pethidine 77±4 118.7±6.2 79.5±6.3
P 0.367 0.664 0.847
3 h
Paracetamol 76±4 118.3±6.3 77.8±8.3
Pethidine 77±4 119.3±8.4 79.6±7.5
P 0.367 0.343 0.230
4 h
Paracetamol 76±4 119.3±8.5 78.9±8.6
Pethidine 76±4 118.5±5.6 78.5±7.3
P 0.768 0.577 0.811
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of the single-arm pilot study by Ahmed EHE in Cairo[28]
(unpublished data), which showed a significant reduction 
in pain perception for up to 3 h after drug (intravenous 
paracetamol) administration but an insignificant reduction at 
15 min. The choice of 15 min as time of first pain assessment 
in the earlier study as against 30 min in this study was because 
intravenous drug was used which has more rapid onset than 
intramuscular drug as in this study. At 4 h, the lowering of 
the mean difference from the pretreatment pain score in 
paracetamol group indicated diminished clinical effect.
An Egyptian study that compared intravenous paracetamol 
and intravenous pethidine as labor analgesic[30] had revealed 
that there was significant pain reduction at 15 min and at 1 
and 2 h in both groups (P < 0.001). The reduction in pain 
was significantly greater in the pethidine group only at 
15 min (P = 0.004). This is similar to what was observed in 
this study with significant and comparable pain reduction in 
both groups at 1, 2, and 3 h (P < 0.001), but pain reduction 
in the pethidine group at 1 h was greater than that of 
paracetamol group (P < 0.001). This difference in time of 
achieving effective pain control between the two studies 
may be due to the different route of drug administration 
with intravenous route achieving minimum inhibitory 
concentration earlier than intramuscular route. However, 
intramuscular route was chosen for the study because it 
is more applicable for low-resource settings such as ours, 
maternity homes, and health centers where most of the 
deliveries take place, and there may be challenges with 
intravenous drug administration in terms of expertise to 
establish and monitor intravenous access.
In this study, there was significant pain reduction up till 3 h 
after paracetamol administration following which there was 
marked decrease in pain reduction at 4 h. This is unlike the 
observation in the Egyptian study where significant pain 
reduction was only achieved for 2 h after drug administration. 
This is probably due to the fact that intravenous route used 
in the Egyptian study had earlier time of onset of action 
and faster clearance from the system; therefore, giving a 
shorter duration of action while intramuscular drugs used 
in this study has slower release into the system and longer 
duration of action.
All pharmacologic methods for intrapartum analgesia 
have drawbacks. Pethidine is a simple and cheap drug for 
the management of labor pain, especially in low-resource 
countries with limited availability of facilities with effective 
methods for pain management during labor. However, its 
maternal adverse effects which include sedation, respiratory 
depression,[36] delayed gastric emptying, nausea, and vomiting 
are limiting its use. In addition, pethidine readily crosses 
the placenta, and neonatal adverse effects which include 
respiratory depression and decreased Apgar scores[37] are of 
great concerns. Regarding this, in the present study, 38.9% 
of women who received pethidine had one or more of the 
following symptoms: dizziness, dryness of the mouth, and 
vomiting. This is similar to the study of Elbohoty et al.[30] 
where 64% of the women who received pethidine had one or 
more of the following symptoms: dizziness, blurred vision, 
dryness of the mouth, dyspnea, tachycardia, vomiting, and 
significant change in blood pressure.
The mean 1-min Apgar score in the pethidine group 
was significantly lower than that of the paracetamol 
group (P < 0.001); however, the comparable 5-min Apgar 
scores and the absence of neonatal ICU admissions in both 
groups despite a difference in drug-to-delivery interval show 
the absence, in both groups, of serious neonatal adverse 
effects. Ten neonates (18.52%) in the pethidine group had 
1‑min	Apgar	 score	≤7.	No	maternal	 adverse	 effects	were	
recorded in the women who received paracetamol, confirming 
the safety and tolerability of paracetamol reported in other 
studies.[38] Paracetamol is a frequently used over-the-counter 
painkiller and antipyretic drug that is commonly used 
by pregnant women. As compared with other analgesics 
including opioids, it has a better favorable safety profile.[39,40]







Fetal heart rate after drug
30 min 141±5 142±4 −1.421 0.158
1 h 140±5 143±4 −2.363 0.020
2 h 141±5 142±4 −0.541 0.590
3 h 142±4 141±4 0.472 0.638
4 h 142±5 141±4 0.428 0.669
Apgar score (min)
1 8 (8‑9) 7 (7‑8) 6.662 <0.001
5 9  (9) 9  (9) 4.329 <0.001
Values  are  given  as mean±SD  for  fetal  heart  rates  (95% CI)  and mode  for Apgar  score. 
SD, Standard deviation; CI, Confidence interval








Apgar score at 1 min ≤7 0 10 (18.52) −0.581 0.562
Apgar score at 5 min ≤7 0 0
Suckling abnormality 0 3 (5.55) 1.766 0.080
Maternal
Dizziness 0 10 (18.5) 2.011 0.047
Vomiting 0 7 (12.9) 2.810 0.006
Dry mouth 0 4 (7.4) 2.059 0.042
Values given are numbers and percentages of side effects as observed in the group
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The drug-to-delivery interval was compared between the 
two study groups. The mean drug-to-delivery interval was 
shorter with paracetamol use (5.2 h) (P = 0.271) as compared 
with pethidine use (5.5 h) although the difference was not 
statistically significant. Similar observation had been made 
by previous studies.[30] This might suggest that paracetamol 
may be associated with shorter duration of active phase of 
labor as compared with pethidine. The potential benefits 
that will be derivable from the reduction of the duration 
of the first stage of labor include a lower incidence of 
complications associated with prolonged labor. Further 
large-scale studies are required to fully unravel and establish 
the effect of paracetamol on the duration of labor which may 
be beneficial to women.
Conclusion
The findings of this study demonstrate the effectiveness of 
intramuscular paracetamol as an intrapartum analgesic with a 
duration of action up till 3 h after administration. Its effect is, 
however, less pronounced than that of pethidine. Paracetamol 
is, however, associated with fewer maternal adverse effects 
and might be associated with shortening of labor duration 
as compared with pethidine. Neonatal outcome profile also 
seems better with paracetamol than pethidine.
Recommendation
Further research with increased dose of intramuscular 
paracetamol which will like give more pain relief is 
recommended.
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